Moreover, OSS-128167, a novel SIRT6-specific inhibitor which can decrease cell viability in primary diffuse large B-cell lymphoma (DLBCL), exerts anti-tumor activity in DLBCL cells. The gene discussed is SIRT6; the disease is diffuse large B-cell lymphoma.